(lp0
S'Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap ... Yahoo Finance - Mar 15, 2017 Antares stock has been on a steady rise for the past year. The company develops and manufactures pressure-assisted injector devices that allow patients to self-inject prescription drugs.'
p1
aS'ANTARES PHARMA, INC.  Files An 8-K Results of Operations and ... Market Exclusive - Mar 14, 2017 Antares Pharma, Inc.  is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.'
p2
aS'Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and ... GlobeNewswire  - Mar 14, 2017 EWING, N.J., March 14, 2017  -- Antares Pharma, Inc.  today reported operating progress and financial results for the fourth quarter and full year ended December 31, 2016.Antares Pharma Inc  Scheduled to Post Quarterly Earnings on Tuesday - The Cerbat GemThe Antares Pharma Inc  to Release Quarterly Earnings on Tuesday - Petro Global News 24'
p3
aS'Antares Pharma Posts Narrower Loss In Q4 - Quick Facts Nasdaq - Mar 14, 2017  - Antares Pharma, Inc.  reported a fourth-quarter net loss of $4.5 million compared to a loss of $6.6 million for the same period in 2015.Antares Pharma reports 4Q loss - Yahoo FinanceAntares Pharma Inc  Trading 6.2% Higher After Earnings Beat - The Cerbat Gem'
p4
aS'Antares Pharma: Realistic Expectations Seeking Alpha - Feb 1, 2017 This article represents an extension to an SA article published December 30, titled &quot;Antares Pharma: Drug Delivery to Multiple Fronts of Profitability&quot;.'
p5
aS'Antares Pharma: Drug Delivery To Multiple Fronts Of Profitability Seeking Alpha - Dec 30, 2016 Over the last several years, investors in Antares Pharma  have experienced multiple disappointments which prompted many shareholders to exit the shares while remaining holders became increasingly impatient, illustrated in the chart below&nbsp;...'
p6
aS'Antares Pharma Announces Completion of the QuickShot Testosterone Clinical Program GlobeNewswire  - Sep 22, 2016 EWING, N.J., Sept. 22, 2016  -- Antares Pharma, Inc.  today announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3 study of QuickShot Testosterone &nbsp;...'
p7
aS'Does Zero-Debt Really Make Antares Pharma Inc  A Financially Strong Company? Simply Wall St - Mar 6, 2017 Any company, including Antares Pharma Inc  with no debt in its capital structure, would maximize capital returns by having an optimal capital structure, which includes debt.'
p8
aS'Investor Toolkit: ERP5 update on Antares Pharma, Inc.  Business Review - Mar 17, 2017 The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.'
p9
aS"Analyst's Proposition on Uranium Energy Corp. , Antares Pharma, Inc.  The USA Commerce - Mar 17, 2017 The share price is now up 54.00% for the past three months. Latest closing price was 0.34% above its 50-day moving average and 38.71% above its 200-day moving average."
p10
a.